Syncom Formulations (India) Limited (SYNCOMF) Fair Value & Analysis
Healthcare · IN · Market cap ₹13.4B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price −3.0% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹10.30 – ₹19.29 · fair‑value band ₹7.41 – ₹21.21 · the ₹14.24 price screens above the ₹13.39 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Syncom Formulations (India) Limited (SYNCOMF) currently trades at ₹14.24, while our model-based Fair Value estimate is ₹13.39 — implying the stock looks roughly 6.0% overvalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Syncom Formulations (India) Limited generated revenue of ₹4.9B at a net margin of 15.6%. Revenue declined 9.0% year over year. It earns a return on equity of 20.2%. The balance sheet holds a net cash position of ₹48.6M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers its pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, liquids orals, and effervescent. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Syncom Formulations (India) Limited reported revenue of ₹4.9B in FY2026 versus ₹2.2B in FY2022, a compound +22.4%/yr. Reported net income was ₹764M in FY2026, compounding +40.2%/yr from FY2022.
Is SYNCOMF fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Syncom Formulations (India) Limited (SYNCOMF) undervalued?
What is the fair value of SYNCOMF?
What is the quality score of SYNCOMF?
What is the revenue of Syncom Formulations (India) Limited (SYNCOMF)?
What is the net profit margin of SYNCOMF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.